At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 7 enrolled
Drug / intervention
Fluticasone propionate (Flovent Diskus) 250 mcg +2 moredrug
Likely dose
Fluticasone propionate (Flovent Diskus) 250 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Does a Lipophilic Steroid Inhaled After an Early Allergic Reaction Affect the Late Reaction?
In Brief
A Phase 4 clinical trial evaluating Fluticasone propionate (Flovent Diskus) 250 mcg, budesonide 400 mcg, and 1 other intervention for Mild Intermittent Asthma. Completed, enrolled 7 participants across 1 site.
Detailed Summary
The investigators propose a 3-treatment, placebo-controlled, double-dummy, double-blinded, randomized, crossover study in which single doses of placebo, will be compared to Fluticasone propionate (Flovent Diskus) 250 mcg and budesonide 400 mcg administered after allergen challenge, at cessation of the early allergic reaction (at 20% fall in FEV1 from post-allergen peak)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Intermittent Asthma
CountriesCanada
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedJul 2008
Primary CompletionNov 2008
Study CompletionDec 2008
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartJul 1, 2008
Primary CompletionNov 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.0 years ago
Interventions
Fluticasone propionate (Flovent Diskus) 250 mcgdrug
Flovent Diskus 250 mcg
budesonide 400 mcgdrug
budesonide 400 mcg
Placeboother
Placebo